Tilray (NASDAQ:TLRY - Get Free Report) posted its quarterly earnings results on Tuesday. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.04) by ($0.06), Zacks reports. The firm had revenue of $185.78 million for the quarter, compared to analysts' expectations of $213.38 million. Tilray had a negative net margin of 30.95% and a negative return on equity of 4.40%. Tilray updated its FY 2025 guidance to EPS.
Tilray Stock Down 3.6 %
NASDAQ:TLRY traded down $0.02 during trading hours on Friday, hitting $0.49. The stock had a trading volume of 22,827,649 shares, compared to its average volume of 29,491,812. Tilray has a 1-year low of $0.44 and a 1-year high of $2.52. The business has a 50 day simple moving average of $0.73 and a two-hundred day simple moving average of $1.17. The company has a current ratio of 2.54, a quick ratio of 1.58 and a debt-to-equity ratio of 0.10. The company has a market cap of $457.01 million, a PE ratio of -1.62 and a beta of 1.88.
Analyst Ratings Changes
A number of brokerages have weighed in on TLRY. Canaccord Genuity Group lifted their price target on shares of Tilray from $2.00 to $3.00 and gave the company a "buy" rating in a research report on Monday, January 13th. Piper Sandler decreased their price target on shares of Tilray from $2.00 to $1.00 and set a "neutral" rating for the company in a research report on Wednesday.
Check Out Our Latest Report on Tilray
Tilray Company Profile
(
Get Free Report)
Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Canada.
Read More
Before you consider Tilray, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tilray wasn't on the list.
While Tilray currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
